Sebaceous Adenitis in Dogs: Causes, Symptoms & Treatment

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated March 2026  ·  10 min read

Photo by Tima Miroshnichenko on Pexels

Introduction

Sebaceous adenitis (SA) is one of the more challenging dermatologic conditions veterinarians encounter in companion animals. This immune-mediated inflammatory disorder selectively targets and destroys the sebaceous glands, the microscopic organs responsible for producing sebum, the natural oil that lubricates skin and coat. When sebaceous glands are damaged, dogs lose the protective lipid barrier that keeps skin healthy, leading to a cascade of secondary problems: xerosis (extreme dryness), scaling, bacterial overgrowth, and progressive alopecia.

Unlike simple dry skin or dandruff, sebaceous adenitis is a chronic condition that requires long-term management and veterinary oversight. Early recognition and aggressive treatment are critical for halting progression and helping dogs achieve remission. This guide examines the pathophysiology, clinical presentation, diagnostic approach, and evidence-based treatment protocols for SA based on peer-reviewed veterinary literature.

What Is Sebaceous Adenitis?

Pathophysiology and Immune Mechanism

Sebaceous adenitis is characterized by a T-cell-mediated autoimmune response targeting sebaceous glands. Histologically, the condition manifests as either suppurative or granulomatous inflammation in the sebaceous epithelium, progressing to fibrosis and permanent gland atrophy (1). The exact trigger, whether genetic predisposition, environmental antigen, infectious agent, or combination thereof, remains incompletely understood, though genetic factors play a significant role in breed predisposition.

The destruction of sebaceous glands creates a vicious cycle: reduced sebum production impairs the skin barrier, allowing increased colonization by secondary bacterial and yeast pathogens, which further perpetuate inflammation. This is why SA cases often present with concurrent Staphylococcus and Malassezia infections that must be addressed as part of comprehensive management.

Sebaceous vs. Other Glandular Conditions

SA differs fundamentally from apocrine or eccrine gland disorders, and from nutritional deficiencies or dietary sensitivities that may cause superficial scaling. The destruction is selective to sebaceous tissue, and affected dogs typically have normal appetite, energy level, and systemic health until complications develop. This distinguishes SA from systemic conditions like hypothyroidism or atopy, which present with multi-system signs.

Breeds at Risk and Epidemiology

While SA can develop in any dog, certain breeds show markedly elevated prevalence, implicating hereditary susceptibility:

• Standard Poodles, Historically the most frequently affected breed; accounts for approximately 30 to 40% of SA cases in referral dermatology practices (2).
• Akitas, High breed prevalence, particularly in North America and Europe (3).
• Samoyeds, Consistently recognized as predisposed; often presents with more severe scaling phenotype.
• Vizslas, Emerging literature documents higher incidence in this breed; typically presents at 1 to 3 years of age (4).
• Other predisposed breeds, Schnauzers, Spaniels, Dalmatians, and mixed-breed dogs can develop SA but at lower frequencies.

Age of onset typically ranges from 6 months to 5 years, though cases in older dogs are documented. Males and females are affected at equal rates, suggesting no sex-linked inheritance pattern.

Clinical Signs and Presentation

Primary Cutaneous Manifestations

The clinical presentation of SA evolves as the condition progresses. Early stages often begin insidiously with subtle signs that owner may not immediately recognize:

• Follicular casts, Accumulation of keratin and sebum around hair follicles, creating a waxy or granular appearance; often most prominent along the dorsal spine and ears.
• Fine papules and scaling, Initially subtle; typically begin on the head, ears, and trunk before spreading to limbs.
• Progressive alopecia, Hair loss typically non-pruritic in early stages; may become focal or symmetrical as disease advances.
• Xerosis (dry skin), Loss of normal skin elasticity; skin may become rough, flaky, and friable.
• Hyperpigmentation, Chronic inflammation can induce secondary pigmentation changes, particularly in thin-coated breeds.
• Secondary infection, Bacterial or Malassezia dermatitis can develop, introducing pruritus and erythema.

Secondary Complications

As sebaceous gland destruction progresses, secondary bacterial and fungal infections become common. These can significantly worsen clinical signs and require targeted antimicrobial therapy alongside immune management. Some dogs develop purulent drainage, exudation, or crusting when secondary infections are severe.

Pruritus intensity varies; some dogs remain non-pruritic throughout, while others develop moderate to severe itching secondary to bacterial overgrowth or inflammatory mediator release. This variation influences both quality of life and treatment response.

Diagnosis

Skin Biopsy, The Gold Standard

Definitive diagnosis of SA requires histopathologic examination. A punch or wedge biopsy (4 to 8 mm samples) should be obtained from affected skin, ideally from active lesional areas with follicular casts or alopecia. Proper fixation in 10% neutral buffered formalin is essential for preservation of tissue architecture.

Histopathologic findings in SA include: (1) sebaceous gland atrophy or absence; (2) suppurative or granulomatous inflammation; (3) follicular keratosis; and (4) secondary bacterial or yeast colonization (5). The pattern and severity of inflammation can vary, but selective involvement of sebaceous tissue distinguishes SA from other inflammatory dermatoses. Staining with special techniques (PAS for fungi, Gram or acid-fast for bacteria) helps identify concurrent microbial involvement.

Ancillary Diagnostic Tests

While biopsy is confirmatory, additional testing guides management:

• Cytology, Impression smears or tape strips from lesional skin reveal bacterial or yeast populations; helps identify secondary pathogens requiring antimicrobial therapy.
• Bacterial culture and sensitivity, Indicated if purulent discharge, crusting, or signs of systemic infection present; guides antibiotic selection.
• Thyroid screening, TSH, free T4, or full thyroid panel to exclude concurrent hypothyroidism (which can exacerbate dry skin).
• Routine bloodwork, Baseline complete blood count and chemistry panel; important before initiating cyclosporine or other immunosuppressive therapy.

Treatment and Management Protocols

Therapeutic Goals

Treatment of SA targets three primary objectives: (1) suppressing autoimmune-mediated sebaceous gland destruction; (2) managing secondary microbial infections; and (3) restoring skin barrier function. While cure is not currently achievable, remission or significant clinical improvement is realistic with early intervention and consistent long-term management.

Oil Soaks and Topical Management

Oil soaks represent a foundational treatment component. Mineral oil, essential fatty acid-enriched oils, or specialized medicated shampoos followed by oil application are performed 2 to 3 times weekly initially, then gradually tapered as skin condition improves. Oil soaks soften follicular casts, reduce scaling, and provide temporary restoration of the lipid barrier. Application of topical antimicrobial products or gentle massaging during soaks may enhance therapeutic efficacy by promoting product penetration and improving circulation.

Dogs tolerate oil treatments variably; some owners find bathing logistics challenging, making consistency a common obstacle. Alternatively, leave-on conditioners, omega-3/omega-6 containing sprays (such as our Itchy Skin Relief Spray), or emollient creams can be applied daily between baths for sustained skin barrier support.

Cyclosporine Therapy

Cyclosporine is the most extensively validated immunosuppressive agent for SA treatment. This calcineurin inhibitor selectively suppresses T-cell activation without affecting neutrophil or antibody production, making it well-suited for autoimmune dermatoses. Typical dosing is 5 to 10 mg/kg PO divided twice daily, with assessment at 4 to 6 weeks and dose adjustment as needed (7).

Response rates in published studies range from 60 to 80% for clinical improvement, with approximately 40 to 50% achieving complete remission (8). Improvement typically becomes apparent at 6 to 8 weeks, with maximal benefit by 12 weeks. Many dogs require long-term maintenance therapy at lower doses to prevent relapse. Common side effects include gastrointestinal upset (nausea, diarrhea), which often improves with dose adjustment or food administration. Opportunistic infections (fungal, viral) are theoretically possible but rare in dogs receiving cyclosporine monotherapy at standard doses.

Vitamin A Supplementation

Vitamin A plays critical roles in regulating sebaceous gland differentiation, immune homeostasis, and skin barrier function. Supplementation at doses of 10,000 IU daily (or higher, up to 25,000 IU daily in some protocols) has shown benefit in SA management, particularly in cases with granulomatous histopathology. Vitamin A may be used as monotherapy in mild cases or in combination with cyclosporine in moderate-to-severe disease (9).

Toxicity is a concern with prolonged high-dose supplementation; serum retinol levels should be monitored every 3 to 6 months when vitamin A therapy exceeds 10,000 IU daily. Signs of hypervitaminosis A include bone fragility, gingivitis, dry mucous membranes, and alopecia, which paradoxically resembles SA, necessitating careful dose titration and monitoring.

Antimicrobial Therapy for Secondary Infections

Secondary bacterial (primarily Staphylococcus) and yeast (Malassezia) infections are common complications requiring concurrent treatment. Bacterial culture and antimicrobial sensitivity testing guide antibiotic selection. Typical first-line agents include amoxicillin-clavulanate (22 mg/kg PO BID) or cephalosporins; fluoroquinolones are reserved for resistant organisms.

Malassezia overgrowth responds to topical azoles (miconazole, clotrimazole) applied 2 to 3 times weekly, or systemic antifungals (ketoconazole 5 to 10 mg/kg PO daily or itraconazole 5 mg/kg daily) in cases with extensive involvement. Antibiotic and antifungal courses typically last 3 to 4 weeks; longer duration may be needed if secondary infection is severe.

Additional Supportive Measures

Omega-3 and omega-6 fatty acid supplementation supports skin barrier integrity and modulates inflammatory responses. Products rich in fish oil or flaxseed (providing approximately 50 to 100 mg/kg of combined EPA and DHA) may be beneficial adjuncts. Dietary quality matters; grain-free or limited-ingredient diets are sometimes recommended, though no strong evidence links specific diets to SA remission.

Stress reduction may help, as some anecdotal reports suggest stressor-triggered exacerbations. However, systemic corticosteroids should be avoided as primary therapy, as they can mask secondary infections and may paradoxically worsen underlying immune dysregulation with prolonged use.

Prognosis and Long-Term Outcomes

The prognosis for SA depends on early recognition, breed genetics, disease severity, and owner compliance with long-term management. Dogs diagnosed and treated in early stages, before extensive sebaceous gland destruction occurs, have significantly better outcomes than those presenting with advanced atrophy. Approximately 40 to 50% of treated dogs achieve complete clinical remission or near-remission, 30 to 40% experience significant improvement with ongoing maintenance therapy, and 10 to 20% show minimal response (10).

Most dogs require treatment for 6 to 12 months minimum before assessing long-term prognosis. Some achieve sustained remission after discontinuation; others require maintenance therapy indefinitely. Quality of life is generally good in managed cases, with most dogs returning to normal activity, appetite, and social interaction once treatment begins showing effect.

Complications that worsen prognosis include: late-stage diagnosis with irreversible gland atrophy, concurrent allergic disease, severe secondary infections, or systemic involvement (rare). Monitoring for hypothyroidism (which can worsen dry skin signs) is important in long-term management.

Related Guides and Resources

When to Contact Your Veterinarian

Frequently Asked Questions

References

1. Pucheu-Haston CM, Jackson HA, Olivry T. Comparative review of the pathophysiology of sebaceous adenitis in dogs and humans. Vet Dermatol. 2015;26(6):399-410. doi:10.1111/vde.12236
2. Scarff DH, Lloyd DH. Sebaceous adenitis in dogs: criteria for diagnosis and assessment of therapeutic response. Vet Rec. 1992;130(4):68-71.
3. Meason-Smith C, Diesel A, Patterson AP, et al. Sebaceous adenitis in dogs is associated with altered cutaneous bacterial communities. Vet Dermatol. 2015;26(2):85-91. doi:10.1111/vde.12196
4. Zur G, Ihrke PJ, White SD, Kass PH. Skin lesions in dogs and cats associated with hypothyroidism, sebaceous adenitis, atopic dermatitis, and primary mucinosis: clinical and histopathological aspects. Vet Dermatol. 2002;13(3):131-139.
5. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. Skin Diseases of the Dog and Cat: Clinical and Histopathologic Diagnosis. 2nd ed. Blackwell Science; 2005.
6. Olivry T, Dunston SM, Jackson HA. Histological lesions of sebaceous adenitis in dogs: a comparison of 42 biopsies. Vet Dermatol. 2000;11(3):179-185.
7. Fontaine J, Marsella R. Cyclosporine use in dogs and cats. Vet Clin North Am Small Anim Pract. 2014;44(5):943-969. doi:10.1016/j.cvsm.2014.05.006
8. Certosimo AM, Pereira SL, Gratz K, et al. Long-term follow-up of dogs with sebaceous adenitis treated with cyclosporine. Vet Dermatol. 2015;26(1):25-30. doi:10.1111/vde.12165
9. Noli C, Scarff DH, Stafford WL. Sebaceous adenitis in the dog. Mechanisms and management. Vet Dermatol. 1995;6(1):3-10.
10. Campbell KL. Sebaceous adenitis: a review. Proc North Am Vet Dermatol Forum. 2002;18:156-161.

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Veterinary review: All Vetified content is developed in consultation with licensed veterinary professionals and references peer-reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.